New Delhi: Bharat Biotech’s intranasal Covid vaccine received approval from the Drugs Controller General of India (DCGI) on Tuesday, for restricted emergency use in those aged above 18 years.
Lauding the achievement, Health Minister Dr Mansukh Mandaviya said, it is a “Big Boost to India’s Fight Against COVID-19.”
Big Boost to India’s Fight Against COVID-19!
Bharat Biotech’s ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation.
— Dr Mansukh Mandaviya (@mansukhmandviya) September 6, 2022
Bharat Biotech stated last month that it had conducted two separate trials for its intranasal Covid vaccine, one as a primary dose schedule and another as a booster dose, with over 4000 volunteers, for those who have been double vaccinated with the two commonly administered Covid vaccines in India.
The volunteers had no side effects or reactions reported so far and proven to be safe, well-tolerated, and immunogenic, Bharat Biotech said.
It is the first intranasal vaccine for COVID-19 in the country.
The Minister further tweeted that this step will strengthen our collective fight against the pandemic. “India has harnessed its science, research and development, and human resources in the fight against COVID-19 under PM Narendra Modi’s leadership. With the science-driven approach and Sabka Prayas, we will defeat COVID-19.”
Click here for Latest News updates and viral videos on our AI-powered smart news
For viral videos and Latest trends subscribe to NewsMobile YouTube Channel and Follow us on Instagram